Oncology company NeoPhore Limited revealed on Monday the election of Matthew Baker PhD as its chief executive officer (CEO), with immediate effect.
Prior to the promotion, Dr Baker has served as the vice president of Immunology at NeoPhore and will succeed the outgoing Jeff Roix.
Previously, Dr Baker was employed as the chief scientific officer of Denceptor Therapeutics Ltd and Abzena plc , chief executive officer and cofounder of Antitope Ltd and vice president for Biologics Discovery at Biovation Ltd.
Currently, Dr Baker is the non-executive director at Oxgene Ltd.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886